Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorbugallo, ana
dc.contributor.authorMuiño, Elena
dc.contributor.authorHervella, Pablo
dc.contributor.authorArias-Rivas, Susana
dc.contributor.authorRodríguez-Yáñez, Manuel
dc.contributor.authorMaisterra Santos, Olga
dc.contributor.authorPizarro Gonzálvez, Jesús
dc.contributor.authorBravo Lopez, Susana Belén
dc.date.accessioned2025-04-04T06:26:04Z
dc.date.available2025-04-04T06:26:04Z
dc.date.issued2025-02-27
dc.identifier.citationBugallo-Casal A, Muiño E, Bravo SB, Hervella P, Arias-Rivas S, Rodríguez-Yáñez M, et al. NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL. NeuroMolecular Med. 2025 Feb 27;27:18.
dc.identifier.issn1559-1174
dc.identifier.urihttp://hdl.handle.net/11351/12894
dc.descriptionDisease modeling; Proteomic analysis; Stem cells
dc.description.abstractCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common genetic form of stroke. It is caused by a cysteine-altering variant in one of the 34 epidermal growth factor-like repeat (EGFr) domains of Notch3. NOTCH3 pathogenic variants in EGFr 1–6 are associated with high disease severity, whereas those in EGFr 7–34 are associated with late stroke onset and increased survival. However, whether and how the position of the NOTCH3 variant directly affects the disease severity remains unclear. In this study, we aimed to generate human-induced pluripotent stem cells (hiPSCs) from patients with CADASIL with EGFr 1–6 and 7–34 pathogenic variants to evaluate whether the NOTCH3 position affects the cell phenotype and protein profile of the generated hiPSCs lines. Six hiPSCs lines were generated: two from patients with CADASIL with EGFr 1–6 pathogenic variants, two from patients with EGFr 7–34 variants, and two from controls. Notch3 aggregation and protein profiles were tested in the established six hiPSCs lines. Cell analysis revealed that the NOTCH3 variants did not limit the cell reprogramming efficiency. However, EGFr 1–6 variant position was associated with increased accumulation of Notch3 protein in pluripotent stem cells and proteomic changes related with cytoplasmic reorganization mechanisms. In conclusion, our analysis of hiPSCs derived from patients with CADASIL support the clinical association between the NOTCH3 variant position and severity of CADASIL.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesNeuroMolecular Medicine;27
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMalalties cerebrovasculars - Aspectes genètics
dc.subjectCèl·lules mare adultes
dc.subjectAnomalies cromosòmiques
dc.subject.meshCADASIL
dc.subject.mesh/genetics
dc.subject.meshInduced Pluripotent Stem Cells
dc.subject.meshGenetic Variation
dc.subject.meshStroke
dc.titleNOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12017-025-08840-6
dc.subject.decscadasil
dc.subject.decs/genética
dc.subject.decscélulas madre pluripotentes inducidas
dc.subject.decsvariación genética
dc.subject.decsaccidente cerebrovascular
dc.relation.publishversionhttps://doi.org/10.1007/s12017-025-08840-6
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bugallo Casal A] Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. University of Santiago de Compostela (USC), Santiago de Compostela, Spain. [Muiño E] Stroke Pharmacogenomics and Genetics, Sant Pau Institute of Research (IR Sant Pau), Barcelona, Spain. Epilepsy Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Bravo SB] Proteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. [Hervella P] Neuroimaging and Biotechnology Laboratory Group (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. [Arias Rivas S, Rodríguez Yáñez M] Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain. [Maisterra Santos O, Pizarro Gonzálvez J] Unitat de Trastorns de Memòria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Demències, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid40016442
dc.identifier.wos001435375600001
dc.relation.projectidinfo:eu-repo/grantAgreement/EC/H2020/825575
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record